ATE126269T1 - Fledermausspeichel-plasminogenaktivatoren. - Google Patents

Fledermausspeichel-plasminogenaktivatoren.

Info

Publication number
ATE126269T1
ATE126269T1 AT89307411T AT89307411T ATE126269T1 AT E126269 T1 ATE126269 T1 AT E126269T1 AT 89307411 T AT89307411 T AT 89307411T AT 89307411 T AT89307411 T AT 89307411T AT E126269 T1 ATE126269 T1 AT E126269T1
Authority
AT
Austria
Prior art keywords
plasminogen activators
glycoprotein
bat saliva
saliva plasminogen
bat
Prior art date
Application number
AT89307411T
Other languages
English (en)
Inventor
Le Thi Duong
John W Jacobs
Paul A Friedman
Richard A F Dixon
Stephen J Gardell
George E Mark
Bruce L Daugherty
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of ATE126269T1 publication Critical patent/ATE126269T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT89307411T 1988-07-20 1989-07-20 Fledermausspeichel-plasminogenaktivatoren. ATE126269T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22169788A 1988-07-20 1988-07-20
US37722189A 1989-07-13 1989-07-13

Publications (1)

Publication Number Publication Date
ATE126269T1 true ATE126269T1 (de) 1995-08-15

Family

ID=26916041

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89307411T ATE126269T1 (de) 1988-07-20 1989-07-20 Fledermausspeichel-plasminogenaktivatoren.

Country Status (17)

Country Link
US (1) US5830849A (de)
EP (1) EP0352119B1 (de)
JP (1) JP2713467B2 (de)
KR (1) KR0138997B1 (de)
AT (1) ATE126269T1 (de)
AU (1) AU621389B2 (de)
CA (1) CA1341090C (de)
DE (1) DE68923741T2 (de)
DK (1) DK176140B1 (de)
ES (1) ES2076965T3 (de)
FI (1) FI100403B (de)
GR (1) GR3017587T3 (de)
IE (1) IE69054B1 (de)
IL (1) IL91059A (de)
NO (2) NO302954B1 (de)
NZ (1) NZ230017A (de)
PT (1) PT91236B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01500322A (ja) * 1986-03-28 1989-02-09 クリエイティブ　バイオモレクレス，インコーポレーテッド 組織プラスミノーゲンアクテイベーター類縁蛋白質
US6008019A (en) * 1989-02-13 1999-12-28 Schering Aktiengesellschaft Plasminogen activator from saliva of the vampire bat
ES2085326T3 (es) * 1989-02-13 1996-06-01 Schering Ag Activador de plasminogeno salivar del murcielago vampiro vpa-alfa1.
DE3943241A1 (de) * 1989-12-22 1991-06-27 Schering Ag Thrombolytisch wirkendes kombinationspraeparat
EP0455424A3 (en) * 1990-05-02 1992-04-29 Merck & Co. Inc. Mammalian inducible promoter cascade system
JPH06506459A (ja) * 1991-04-16 1994-07-21 ロシュ ダイアグノスティックス ゲーエムベーハー プラスミノーゲン活性化剤を含有する多重ボーラス投与用医薬パッケージユニット
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke
US5731186A (en) * 1996-02-05 1998-03-24 Schering Aktiengesellschaft Method for the production of rDSPA α1
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
AU2003227721A1 (en) * 2003-05-02 2004-11-23 Paion Gmbh Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
US20060135425A1 (en) * 2003-05-02 2006-06-22 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
EP1622639B1 (de) * 2003-05-02 2013-01-16 Lundbeck, H., A/S Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall
DE10342518A1 (de) * 2003-09-12 2005-05-12 Paion Gmbh Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
AR068914A1 (es) * 2007-10-18 2009-12-16 Paion Deutschland Gmbh Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia
EP2289541A1 (de) 2009-08-31 2011-03-02 PAION Deutschland GmbH Behandlung von neurologischen und neurodegenerativen Erkrankungen
EP2289542A1 (de) 2009-08-31 2011-03-02 PAION Deutschland GmbH Behandlung von neurologischen und neurodegenerativen Erkrankungen
TWI866194B (zh) 2017-02-03 2024-12-11 法商艾提寇生物技術公司 使用抗人類ｇｐｖｉ抗體抑制血小板凝集
EP3624832B1 (de) 2017-05-16 2025-08-20 Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzungen zur behandlung von akutem ischämischem schlaganfall
EP3806833A1 (de) 2018-06-15 2021-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Verwendung von pi3kc2b-inhibitoren zur erhaltung der integrität der vaskulären endothelialen zellbarriere
BR112021015431A2 (pt) * 2019-02-05 2021-10-05 Dyno Nobel Asia Pacific Pty Limited Grânulos de nitrato de amônio estabilizado por fase e produtos e métodos relacionados
WO2021148439A1 (en) 2020-01-21 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stimulating cerebrovascular function
EP4161579A1 (de) 2020-06-09 2023-04-12 Institut National de la Santé et de la Recherche Médicale (INSERM) Fucoidanfunktionalisierte polysaccharidpartikel mit t-pa zur gezielten thrombolytischen therapie
WO2023156683A1 (en) 2022-02-21 2023-08-24 Acticor Biotech Treatment of cardiovascular diseases using anti-human gpvi antibodies
EP4556492A1 (de) 2023-11-14 2025-05-21 Acticor Biotech Behandlung von herz-kreislauf-erkrankungen mit anti-humanen gpvi-antikörpern in subpopulationen von personen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US5010002A (en) * 1983-01-19 1991-04-23 Genentech, Inc. Human t-PA production using vectors coding DHFR protein
ATE90967T1 (de) * 1986-03-28 1993-07-15 Creative Biomolecules Inc Proteinanaloge des gewebs-plasminogenaktivators.
AU605364B2 (en) * 1987-10-09 1991-01-10 Monsanto Company Modified tissue plasminogen activator
ES2085326T3 (es) * 1989-02-13 1996-06-01 Schering Ag Activador de plasminogeno salivar del murcielago vampiro vpa-alfa1.

Also Published As

Publication number Publication date
NO302954B1 (no) 1998-05-11
JP2713467B2 (ja) 1998-02-16
FI893500L (fi) 1990-01-21
IE892354L (en) 1990-01-20
FI893500A0 (fi) 1989-07-19
EP0352119A3 (en) 1990-07-04
AU3891589A (en) 1990-01-25
US5830849A (en) 1998-11-03
ES2076965T3 (es) 1995-11-16
PT91236B (pt) 1995-03-01
NO970603L (no) 1990-01-22
FI100403B (fi) 1997-11-28
EP0352119A2 (de) 1990-01-24
NO892976D0 (no) 1989-07-20
DK357589D0 (da) 1989-07-19
DK357589A (da) 1990-01-23
CA1341090C (en) 2000-08-29
IE69054B1 (en) 1996-08-07
NO970603D0 (no) 1997-02-10
NZ230017A (en) 1992-05-26
NO314548B1 (no) 2003-04-07
DE68923741T2 (de) 1996-02-15
DE68923741D1 (de) 1995-09-14
IL91059A (en) 1995-06-29
PT91236A (pt) 1990-02-08
KR0138997B1 (ko) 1998-04-30
GR3017587T3 (en) 1995-12-31
EP0352119B1 (de) 1995-08-09
JPH02167075A (ja) 1990-06-27
AU621389B2 (en) 1992-03-12
KR910003094A (ko) 1991-02-26
DK176140B1 (da) 2006-09-25
IL91059A0 (en) 1990-02-09
NO892976L (no) 1990-01-22

Similar Documents

Publication Publication Date Title
ATE126269T1 (de) Fledermausspeichel-plasminogenaktivatoren.
ES8802442A1 (es) Un procedimiento para preparar un polimero de adn.
EP0814154A3 (de) Rekombinante Alphavirus-Vektoren
AU4194689A (en) Tissue plasminogen activator having zymogenic or fibrin specific properties
AU6683086A (en) Novel peptide plasminogen activators
ATE79273T1 (de) Stabilisierte zusammensetzungen von menschlichen aktivatoren des gewebeplasminogens.
EP0714435A4 (de) Mutanten der pro-urokinase
NO20021501L (no) Fibrinolyttisk aktivt polypeptid
NO179754C (no) Fremgangsmåte for fremstilling av en t-PA-analog, DNA-sekveks som koder for t-PA-analogen, ekspresjonsvektor omfattende DNA-sekvensen samt vertscelle omfattende denne
WO1988005081A3 (en) Novel plasminogen activator
AU679512B2 (en) Bifunctional variants of urokinase with improved fibrinolytic properties and thrombin-inhibiting activity
DK203588A (da) Fremgangsmaade til fremstilling af proteiner
DK0444775T3 (da) Rekombinant-DNA-ekspressionsvektorer og DNA-forbindelser, som koder for isopenicillin-N-epimerase-ak tivitet
FI932196A0 (fi) Foerfarande foer bestaemning av fibrinogen
EP0381331A3 (de) Gensequenzen, die modifizierte Reste in der Proteasedomäne des t-PAs codieren
AU1200388A (en) A method for the functional determination of protein c inhibitor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time